JP2008534594A5 - - Google Patents

Download PDF

Info

Publication number
JP2008534594A5
JP2008534594A5 JP2008504193A JP2008504193A JP2008534594A5 JP 2008534594 A5 JP2008534594 A5 JP 2008534594A5 JP 2008504193 A JP2008504193 A JP 2008504193A JP 2008504193 A JP2008504193 A JP 2008504193A JP 2008534594 A5 JP2008534594 A5 JP 2008534594A5
Authority
JP
Japan
Prior art keywords
chlamydia
serotype
chlamydia trachomatis
composition
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008504193A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008534594A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/010793 external-priority patent/WO2006104890A2/en
Publication of JP2008534594A publication Critical patent/JP2008534594A/ja
Publication of JP2008534594A5 publication Critical patent/JP2008534594A5/ja
Pending legal-status Critical Current

Links

JP2008504193A 2005-03-31 2006-03-24 クラミジア感染に対するワクチン Pending JP2008534594A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66733105P 2005-03-31 2005-03-31
PCT/US2006/010793 WO2006104890A2 (en) 2005-03-31 2006-03-24 Vaccines against chlamydial infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012115243A Division JP2012180367A (ja) 2005-03-31 2012-05-21 クラミジア感染に対するワクチン

Publications (2)

Publication Number Publication Date
JP2008534594A JP2008534594A (ja) 2008-08-28
JP2008534594A5 true JP2008534594A5 (enExample) 2009-04-09

Family

ID=36646973

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008504193A Pending JP2008534594A (ja) 2005-03-31 2006-03-24 クラミジア感染に対するワクチン
JP2012115243A Pending JP2012180367A (ja) 2005-03-31 2012-05-21 クラミジア感染に対するワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012115243A Pending JP2012180367A (ja) 2005-03-31 2012-05-21 クラミジア感染に対するワクチン

Country Status (16)

Country Link
US (1) US20090022755A1 (enExample)
EP (5) EP2386314A1 (enExample)
JP (2) JP2008534594A (enExample)
KR (1) KR20070121814A (enExample)
CN (2) CN101184504A (enExample)
AU (1) AU2006229968A1 (enExample)
BR (1) BRPI0609547A2 (enExample)
CA (1) CA2602637A1 (enExample)
EA (2) EA201001322A1 (enExample)
IL (1) IL186264A0 (enExample)
MA (1) MA30250B1 (enExample)
MX (1) MX2007012108A (enExample)
NO (1) NO20075069L (enExample)
SG (1) SG158145A1 (enExample)
UA (1) UA97943C2 (enExample)
WO (1) WO2006104890A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213264A1 (en) * 1998-12-08 2008-09-04 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1891096A2 (en) * 2005-05-12 2008-02-27 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for chlamydia trachomatis
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US9259463B2 (en) * 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
HUE031411T2 (en) 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
US20100310593A1 (en) * 2007-06-14 2010-12-09 Emergent Product Development Gaithersburg Inc. Vaccines Against Chlamydia Infection
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
AU2010207828B2 (en) 2009-01-29 2016-07-14 British Columbia Cancer Agency Branch Compositions comprising Chlamydia antigens
IL208820A0 (en) * 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
US8735543B2 (en) 2010-05-28 2014-05-27 Spixia Biotechnology Ab Chimeric MOMP antigen
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
KR101275263B1 (ko) * 2011-04-01 2013-06-14 서울대학교산학협력단 조류 병원성 대장균 특이 박테리오파지 및 이를 포함하는 항균 조성물
US8785145B2 (en) 2011-08-11 2014-07-22 Ingen Biosciences Method for diagnosing gram-negative infections
EP2586789A1 (en) * 2011-08-11 2013-05-01 InGen Biosciences Method for diagnosing gram-negative infections
HK1200724A1 (en) * 2011-09-30 2015-08-14 The University Of British Columbia Chlamydia antigen compositions and uses thereof
CA2878311C (en) 2012-05-29 2021-03-16 The Research Foundation For The State University Of New York Combined therapy and prophylaxis for genital tract infections
CN104812406A (zh) * 2012-08-08 2015-07-29 英属哥伦比亚大学 衣原体抗原组合物及其用途
WO2015106345A1 (en) 2014-01-16 2015-07-23 Mcmaster University Type iii secretion injectisome proteins for treatment and prevention of chlamydial infections
EP3220962A4 (en) * 2014-11-21 2018-07-25 Merck Sharp & Dohme Corp. Recombinant expression of chlamydia momp antigen
US10688171B2 (en) 2015-02-10 2020-06-23 Ohio State Innovation Foundation Chlamydia-activated B cell platforms and methods thereof
US10835601B2 (en) 2015-11-10 2020-11-17 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
RU2676768C2 (ru) * 2016-05-12 2019-01-11 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Противохламидийная вакцина и способ ее получения
CA3057318A1 (en) * 2017-03-23 2018-09-27 Ohio State Innovation Foundation Recombinant chlamydia-activated b cell platforms and methods of use thereof
CN108623657B (zh) * 2018-05-11 2021-02-12 苏州大学 多肽、重组dna分子、重组载体、外泌体及其应用
MX2023008986A (es) * 2021-01-29 2023-08-15 Inst Nat Sante Rech Med Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna.
WO2025076039A1 (en) * 2023-10-03 2025-04-10 The University Of North Carolina At Chapel Hill Chlamydial protease-like activity factor and adjuvant compositions and uses thereof
WO2025076210A1 (en) * 2023-10-03 2025-04-10 Vaxcyte, Inc. Chlamydia vaccine compositions

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AU2613988A (en) 1988-01-04 1989-08-01 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
KR920007887B1 (ko) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 내연기관의 배기가스 정화장치
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
DE69126620T2 (de) 1990-10-18 1997-10-02 Cellpro Inc Vorrichtung und verfahren zur trennung von partikeln mittels eines biegsamen gefässes
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
EP0598816B1 (en) 1991-08-15 1999-06-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
DE69312487T2 (de) 1992-05-18 1997-11-27 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
WO1994015635A1 (en) 1993-01-11 1994-07-21 Dana-Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
GB9626864D0 (en) * 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0832282A1 (en) 1995-06-02 1998-04-01 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
BR9814912A (pt) 1997-11-28 2000-10-03 Genset Sa Sequência genÈmica e polipeptìdeos de chlamydia trachomatis, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
DE69942214D1 (de) 1998-02-05 2010-05-12 Glaxosmithkline Biolog Sa Verfahren zur Reinigung oder Herstellung der MAGE Protein
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
DK1104306T3 (da) 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6447779B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US6432916B1 (en) 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6448234B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6166177A (en) * 1998-12-08 2000-12-26 Corixa Corporation Compounds and methods for the treatment and diagnosis of chlamydial infection
EP2277892A3 (en) * 1998-12-08 2011-04-27 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6555115B1 (en) * 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6811783B1 (en) * 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
ATE389020T1 (de) 2000-04-21 2008-03-15 Corixa Corp Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020146776A1 (en) * 2000-04-21 2002-10-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US7537772B1 (en) * 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
GB0103169D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2002079244A2 (en) * 2001-03-30 2002-10-10 University Of Manitoba Chlamydial protease-like activity factor responsible for degradation of host transcription factor
US20030199438A1 (en) * 2001-04-09 2003-10-23 Shaw Allan Christian Method for identification of proteins from intracellular bacteria
US6770753B2 (en) * 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
ES2312649T3 (es) * 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
JP4896715B2 (ja) * 2003-06-26 2012-03-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫原性組成物
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
US7892567B2 (en) * 2007-10-01 2011-02-22 Board Of Regents, The University Of Texas System Methods and compositions for immunization against chlamydial infection and disease

Similar Documents

Publication Publication Date Title
JP2008534594A5 (enExample)
Jeong et al. CX3CR1 is expressed in differentiated human ciliated airway cells and co-localizes with respiratory syncytial virus on cilia in a G protein-dependent manner
CN106103471B (zh) 异源寡聚分枝杆菌抗原的融合
Morgan et al. Segregation of B and T cell epitopes of Treponema pallidum repeat protein K to variable and conserved regions during experimental syphilis infection
JP2009515831A5 (enExample)
JP2010505795A5 (enExample)
JP2010162023A5 (enExample)
JP2012180367A (ja) クラミジア感染に対するワクチン
HRP20171694T1 (hr) Novi pripravci i postupci
JP2012511545A5 (enExample)
JP2012501959A5 (enExample)
JP2006506942A5 (enExample)
JP2010166921A5 (enExample)
JP5132939B2 (ja) ＨａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅＩＶ型ピリ線毛
JP2007526318A5 (enExample)
JP2010535504A5 (enExample)
JP4399260B2 (ja) 神経再生ペプチドおよび脳損傷治療におけるその使用方法
JP2023540778A (ja) Ａｃｅ２結合力が減少したコロナウイルス由来の受容体結合ドメイン変異体及びこれを含むワクチン組成物
Lin et al. Molecular characterization of three major outer membrane proteins, TSA56, TSA47 and TSA22, in Orientia tsutsugamushi
JP2019526261A5 (enExample)
Lim Extraintestinal manifestations of H. pylori infection: heart disease
ES2551699T3 (es) Composiciones, procedimientos y kits
JP2013510823A (ja) 寄生虫症に対するワクチンまたは診断法としてのｌ３および／またはｌ５供給源の使用
CN101921310B (zh) 登革病毒特异性hla-a2限制性表位肽及应用
US20230313325A1 (en) Methods for detection of pathogenic infections using red blood cell-containing patient samples